keyword
MENU ▼
Read by QxMD icon Read
search

Macular edema anti-VEGF

keyword
https://www.readbyqxmd.com/read/28031700/long-term-results-of-combination-therapy-using-anti-vegf-agents-and-dexamethasone-intravitreal-implant-for-retinal-vein-occlusion-an-investigational-case-series
#1
Michael A Singer, Michael E Jansen, Lyndon Tyler, Paul Woods, Faisal Ansari, Udit Jain, Joshua Singer, Darren Bell, Chelsey Krambeer
BACKGROUND: One limitation of anti-VEGF therapy is the need for monthly retreatment to maintain efficacy. The purpose of this study was to determine the duration of effect in eyes with macular edema (ME) secondary to branch or central retinal vein occlusion (BRVO or CRVO) treated with anti-VEGF therapy plus sustained-release dexamethasone (DEX implant; Ozurdex). MATERIALS AND METHODS: This open-label, interventional case series included 62 eyes with ME due to RVO, central foveal thickness (CFT) >300 μm, and best-corrected visual acuity (BCVA) of 20/40 or worse...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/27983657/fingolimod-associated-bilateral-cystoid-macular-edema-wait-and-see
#2
REVIEW
Refik Pul, Alma Osmanovic, Holger Schmalstieg, Amelie Pielen, Kaweh Pars, Philipp Schwenkenbecher, Kurt Wolfram Sühs, Özlem Yildiz, Benedikt Frank, Martin Stangel, Thomas Skripuletz
Fingolimod 0.5-mg once-daily is an approved therapy for patients with relapsing-remitting multiple sclerosis (MS). Several pivotal and real-world studies have demonstrated that fingolimod is associated with the development of macular edema (ME). Herein, we present a case of a diabetic MS patient who developed severe bilateral ME during fingolimod treatment. By means of this case study we provide a detailed review about fingolimod associated macular edema (FAME), its current incidence with or without diabetes mellitus, and previous therapy attempts and outcomes in MS patients...
December 14, 2016: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/27974593/lebecetin-a-c-type-lectin-inhibits-choroidal-and-retinal-neovascularization
#3
Fadoua Montassar, Marie Darche, Amandine Blaizot, Sébastien Augustin, Jean-Baptiste Conart, Aurélie Millet, Mohamed Elayeb, José-Alain Sahel, Annabelle Réaux-Le Goazigo, Florian Sennlaub, Naziha Marrakchi, Erij Messadi, Xavier Guillonneau
Angiogenesis is a cause of visual impairment and blindness in the wet form of age-related macular degeneration and in ischemic retinopathies. Current therapies include use of anti-VEGF agents to reduce choroidal neovascularization (CNV) and edema. These treatments are effective in most cases, but spontaneous or acquired resistance to anti-VEGF and possible adverse effects of long-term VEGF inhibition in the retina and choroid highlight a need for additional alternative therapies. Integrins αvβ3 and αvβ5, which regulate endothelial cell proliferation and stabilization, have been implicated in ocular angiogenesis...
December 14, 2016: FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology
https://www.readbyqxmd.com/read/27958226/correlation-of-vascular-endothelial-growth-factor-production-with-photochemical-reaction-induced-retinal-edema
#4
Liang Shan, Mi Zheng, Yuan Zhang, Yuan Qu, Tian Niu, Qing Gu, Kun Liu, Xin Xia
BACKGROUND: Retinal edema is the major complication of retinal vein occlusion and diabetic retinopathy; it can damage visual function by influencing macular region. This study was to establish a rat retinal edema model and explore the related VEGF expression and observe the responses to anti-VEGF drugs in this model. METHODS: A rat retinal edema model was established by inducing photochemical reaction using a 532 nm laser after the intravenous injection of Erythrosin B...
2016: Chinese Medical Journal
https://www.readbyqxmd.com/read/27918469/dietary-compound-chrysin-inhibits-retinal-neovascularization-with-abnormal-capillaries-in-db-db-mice
#5
Min-Kyung Kang, Sin-Hye Park, Yun-Ho Kim, Eun-Jung Lee, Lucia Dwi Antika, Dong Yeon Kim, Yean-Jung Choi, Young-Hee Kang
Diabetic retinopathy (DR) develops in a significant proportion of patients with chronic diabetes, characterized by retinal macular edema and abnormal retinal vessel outgrowth leading to vision loss. Chrysin, a naturally-occurring flavonoid found in herb and honeycomb, has anti-inflammatory, antioxidant, and anti-cancer properties. This study sought to determine the protective effects of chrysin on retinal neovascularization with abnormal vessels and blood-retinal barrier (BRB) breakdown in 33 mM glucose-exposed human retinal endothelial cells and in db/db mouse eyes...
December 3, 2016: Nutrients
https://www.readbyqxmd.com/read/27865689/retinal-oximetry-during-treatment-of-retinal-vein-occlusion-by-ranibizumab-in-patients-with-high-blood-pressure-and-dyslipidemia
#6
C Keilani, A Halalchi, D Wakpi Djeugue, A Regis, S Abada
INTRODUCTION: In the present study, we examined retinal vascular oxygen saturation in patients with retinal vein occlusion (RVO), high blood pressure (HBP) and dyslipidemia, before and during intravitreal vascular endothelial growth factor (VEGF) injection (ranibizumab). METHODS: We retrospectively reviewed the medical records of six patients with visual acuity (VA) reduced by macular edema (ME) secondary to RVO with HBP and dyslipidemia, who underwent intravitreal anti-VEGF injection between October 2014 and February 2015 in the department of ophthalmology of François-Quesnay Hospital at Mantes-la-Jolie (France)...
December 2016: Journal Français D'ophtalmologie
https://www.readbyqxmd.com/read/27863843/score2-report-2-study-design-and-baseline-characteristics
#7
Ingrid U Scott, Paul C VanVeldhuisen, Michael S Ip, Barbara A Blodi, Neal L Oden, Maria Figueroa, Pravin U Dugel
PURPOSE: To describe the design and baseline characteristics of participants in the Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2) and to compare with cohorts from other retinal vein occlusion trials. DESIGN: Phase III prospective, multicenter, randomized clinical trial designed to assess whether intravitreal bevacizumab is noninferior to intravitreal aflibercept for treatment of decreased vision attributable to macular edema associated with central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO)...
November 15, 2016: Ophthalmology
https://www.readbyqxmd.com/read/27853011/long-term-effect-of-anti-vascular-endothelial-growth-factor-injections-on-intraocular-pressure
#8
Ashiyana Nariani, Blake Williams, Seenu M Hariprasad
OBJECTIVE: There is a substantial debate in the ophthalmology community about whether anti-vascular endothelial growth factor (VEGF) injections result in a long-term increase in intraocular pressure (IOP). DESIGN: We performed a retrospective study to investigate how the number and timing of intravitreal injections in patients with age-related macular degeneration (AMD) and diabetic macular edema (DME) affect IOP over time. METHODS: We collected long-term IOP data on patients receiving anti-VEGF injections at our institution...
September 2016: Indian Journal of Ophthalmology
https://www.readbyqxmd.com/read/27847634/initiation-of-intravitreal-aflibercept-injection-treatment-in-patients-with-diabetic-macular-edema-a-review-of-vivid-dme-and-vista-dme-data
#9
Focke Ziemssen, Patricio G Schlottman, Jennifer I Lim, Hansjürgen Agostini, Gabriele E Lang, Francesco Bandello
BACKGROUND: Diabetic macular edema (DME) shows a gradual and sustained functional and morphologic response to anti-vascular endothelial growth factor (VEGF) drugs, but the optimal schedule for initiation of anti-VEGF therapy is not known. This study evaluates the treatment response behavior of DME in the Phase 3 trials of intravitreal aflibercept, with 5 initial intravitreal aflibercept injections (IAI), 2 mg every 4 weeks (2q4), in the upload phase. METHODS: This post hoc pooled analysis of the VISTA-DME (NCT01363440) and VIVID-DME (NCT01331681) trials evaluated the change in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) during the upload phase, using pooled data from both IAI treatment groups [2q4 and 2 mg every 8 weeks (2q8)]...
2016: International Journal of Retina and Vitreous
https://www.readbyqxmd.com/read/27826179/efficacy-of-single-bevacizumab-injection-as-adjuvant-therapy-to-laser-photocoagulation-in-macular-edema-secondary-to-branch-retinal-vein-occlusion
#10
Arief S Kartasasmita, Siska Takarai, Astriviani Switania, Sutarya Enus
BACKGROUND: Macular grid laser photocoagulation remains the standard treatment for macular edema secondary to branch retinal vein occlusion (BRVO). One possible strategy for treating macular edema is to inhibit VEGF activity by competitive binding of VEGF with an anti-VEGF antibody, suggesting the therapy option with bevacizumab. However, multiple injections of anti-VEGF may lead to complications and high cost. PURPOSE: The aim of this study was to evaluate the improvement in visual acuity and central macular thickness after combination therapy of laser photocoagulation with single intravitreal bevacizumab injection in macular edema secondary to BRVO...
2016: Clinical Ophthalmology
https://www.readbyqxmd.com/read/27815789/corticosteroids-and-anti-complement-therapy-in-retinal-diseases
#11
Raja Narayanan, Baruch D Kuppermann
Corticosteroids are unique in that they are the one class of agents that acts upon most of the multiple processes in the pathophysiology of macular edema. Corticosteroids are capable of inhibiting prostaglandin and leukotriene synthesis as well as interfering with intercellular adhesion molecule-1 (ICAM-1), interleukin-6, VEGF-A, and stromal cell derived factor-1 pathways. Triamcinolone, dexamethasone, and fluocinolone have been extensively used in the treatment of retinal and choroidal vascular diseases. Sustained release implants of steroids have reduced the burden of repeated intravitreal injections necessary in most of the retinal diseases...
November 5, 2016: Handbook of Experimental Pharmacology
https://www.readbyqxmd.com/read/27815675/-what-can-anti-vegf-therapy-achieve-in-clinical-routine-effectiveness-of-anti-vegf-therapy-in-patients-with-macular-diseases-in-clinical-routine-on-1492-eyes-in-austria
#12
K Wiesinger, P Reinelt, A Ennemoser, M Edelmayr, U Schönherr
BACKGROUND: The aim of this user observational study was to illustrate the effectiveness of intravitreal operative medication administration (IVOM) in the clinical routine. DESIGN: A monocentric, single arm, prospective study. MATERIAL AND METHODS: Included in this study were all patients in whom a macular edema was diagnosed during an ophthalmological examination at the Barmherzigen Brüdern Hospital in Linz from November 2012 to August 2014 and who were treated as outpatients or day clinic patients with IVOM using anti-vascular endothelial growth factor (VEGF)...
November 4, 2016: Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
https://www.readbyqxmd.com/read/27803859/an-eighteen-month-follow-up-study-on-the-effects-of-intravitreal-dexamethasone-implant-in-diabetic-macular-edema-refractory-to-anti-vegf-therapy
#13
Fernanda Pacella, Maria Rosaria Romano, Paolo Turchetti, Giovanna Tarquini, Anna Carnovale, Antonella Mollicone, Alessandra Mastromatteo, Elena Pacella
AIM: To evaluate the long-term efficacy and safety of dexamethasone implants in subjects affected by diabetic macular edema (DME) resistant to anti-vascular endothelial growth factor (VEGF) therapy. METHODS: Thirty-two DME patients were enrolled. A 700 microgram slow release Intravitreal Dexamethasone Implant (Ozurdex(®)) was placed in the vitreous cavity. All patients were followed for 18mo. Best-corrected visual acuity (BCVA) measured with Early Treatment Diabetic Retinopathy Study (ETDRS) and central macular thickness (CMT) exams were carried out at baseline (T0) and after 1 (T1), 3 (T3), 4 (T4), 6 (T6), 9 (T9), 12 (T12), 15 (T15), and 18mo (T18) post injection...
2016: International Journal of Ophthalmology
https://www.readbyqxmd.com/read/27790618/designer-leptin-receptor-antagonist-allo-aca-inhibits-vegf-effects-in-ophthalmic-neoangiogenesis-models
#14
Roberta Coroniti, Rafal Fario, Didier J Nuno, Laszlo Otvos, Laura Scolaro, Eva Surmacz
Experimental and clinical data suggest that pro-angiogenic, pro-inflammatory and mitogenic cytokine leptin can be implicated in ocular neovascularization and other eye pathologies. At least in part, leptin action appears to be mediated through functional interplay with vascular endothelial growth factor (VEGF). VEGF is a potent regulator of neoangiogenesis and vascular leakage with a proven role in conditions such as proliferative diabetic retinopathy, age-related macular degeneration and diabetic macular edema...
2016: Frontiers in Molecular Biosciences
https://www.readbyqxmd.com/read/27784073/retinal-hemodynamics-seen-on-optical-coherence-tomography-angiography-before-and-after-treatment-of-retinal-vein-occlusion
#15
Norihiro Suzuki, Yoshio Hirano, Taneto Tomiyasu, Yuya Esaki, Akiyoshi Uemura, Tsutomu Yasukawa, Munenori Yoshida, Yuichiro Ogura
Purpose: This study evaluates the retinal hemodynamics using optical coherence tomography angiography (OCTA) before and after anti-vascular endothelial growth factor (VEGF) therapy in patients with macular edema associated with retinal vein occlusion (RVO). Methods: Twelve patients (23 eyes; mean age, 64 years) were included (eight eyes with branch RVO, four with central RVO, and 11 unaffected fellow eyes. The best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were measured before and 6 months after treatment...
October 1, 2016: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/27783271/anti-angiogenic-therapy-for-retinal-disease
#16
Yannis M Paulus, Akrit Sodhi
Recent breakthroughs in our understanding of the molecular pathophysiology of retinal vascular disease have allowed us to specifically target pathological angiogenesis while minimizing damage to the neurosensory retina. This is perhaps best exemplified by the development of therapies targeting the potent angiogenic growth factor and vascular permeability mediator, vascular endothelial growth factor (VEGF). Anti-VEGF therapies, initially introduced for the treatment of choroidal neovascularization in patients with age-related macular degeneration, have also had a dramatic impact on the management of retinal vascular disease and are currently an indispensable component for the treatment of macular edema in patients with diabetic eye disease and retinal vein occlusions...
October 26, 2016: Handbook of Experimental Pharmacology
https://www.readbyqxmd.com/read/27769324/effect-of-aflibercept-on-refractory-macular-edema-associated-with-central-retinal-vein-occlusion
#17
Michael N Cohen, Samuel K Houston, Alexander Juhn, Allen C Ho, Carl D Regillo, James Vander, Allen Chiang
OBJECTIVE: To report short-term visual and anatomic outcomes of patients who were switched to aflibercept for persistent macular edema associated with central retinal vein occlusion (CRVO). METHODS: Retrospective, consecutive, interventional case series of 17 patients with persistent macular edema secondary to CRVO (defined as intraretinal edema and either <50 µm reduction in central foveal thickness [CFT] or worsening or no improvement in visual acuity [VA] compared to baseline) despite anti-VEGF treatment who were switched to aflibercept treatment...
October 2016: Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie
https://www.readbyqxmd.com/read/27761468/diabetic-macular-edema-pathophysiology-vasogenic-versus-inflammatory
#18
REVIEW
Pedro Romero-Aroca, Marc Baget-Bernaldiz, Alicia Pareja-Rios, Maribel Lopez-Galvez, Raul Navarro-Gil, Raquel Verges
Diabetic macular edema (DME) can cause blindness in diabetic patients suffering from diabetic retinopathy (DR). DM parameters controls (glycemia, arterial tension, and lipids) are the gold standard for preventing DR and DME. Although the vascular endothelial growth factor (VEGF) is known to play a role in the development of DME, the pathological processes leading to the onset of this disease are highly complex and the exact sequence in which they occur is still not completely understood. Angiogenesis and inflammation have been shown to be involved in the pathogenesis of this disease...
2016: Journal of Diabetes Research
https://www.readbyqxmd.com/read/27759856/optical-coherence-tomography-features-in-diabetic-macular-edema-and-the-impact-on-anti-vegf-response
#19
Yuji Itoh, Daniel Petkovsek, Peter K Kaiser, Rishi P Singh, Justis P Ehlers
BACKGROUND AND OBJECTIVE: To assess the relationship between spectral-domain optical coherence tomography (SD-OCT) features and functional outcomes for diabetic macular edema (DME) undergoing treatment with intravitreal bevacizumab (Avastin; Genentech, South San Francisco, CA). PATIENTS AND METHODS: Institutional review board-approved, retrospective, consecutive case series of eyes receiving intravitreal bevacizumab (1.25 mg) for DME. SD-OCT features were evaluated and correlated with functional response to anti-vascular endothelial growth factor (VEGF) therapy...
October 1, 2016: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/27756077/the-systemic-blood-pressure-and-oxygen-saturation-in-retinal-arterioles-predict-the-effect-of-intravitreal-anti-vegf-treatment-on-diabetic-maculopathy
#20
Toke Bek, Christina Mørup Jørgensen
Purpose: The advent of vascular endothelial VEGF antagonists has increased the therapeutic options for diabetic maculopathy considerably. However, there is a need to identify patients who respond favorably to the treatment from those in whom the treatment is less effective. The purpose of the present study was to test the hypothesis that the oxygen saturation in retinal vessels together with other risk factors can predict the effect of anti-VEGF treatment on diabetic maculopathy. Methods: In 73 eyes from 53 patients with center-involving diabetic macular edema, multiple linear regression was used to evaluate the predictive value of oxygen saturation in larger retinal vessels together with age, diabetes duration, diabetes type, hemoglobin A1c (HbA1c), mean arterial blood pressure (MAP), body mass index (BMI), previous retinal photocoagulation, visual acuity (VA), and central retinal thickness (CRT) before treatment as explanatory variables for VA and CRT after three monthly injections of anti-VEGF medication...
October 1, 2016: Investigative Ophthalmology & Visual Science
keyword
keyword
36615
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"